Abstract: Provided is a Bacillus subtilis natto strain ST-1008, deposited under the accession number CGMCC No. 17894. Also provided is a method for producing MK-7. The method comprises: culturing the Bacillus subtilis natto strain of CGMCC No. 17894 in a culture medium so as to produce MK-7 in the strain cell and the culture medium, and recovering and purifying MK-7 from the strain cell and the culture medium. Also provided are a MK-7 preparation, a MK-7 pure premix, and a pure MK-7.

Abstract: Disclosed are a strain for producing nattokinase and a production method therefor. In particular, the present invention involves a novel strain capable of producing nattokinase, i.e. Bacillus subtilis natto ST-1086, deposited at the China General Microbiological Culture Collection Center under CGMCC No. 17895. The present invention further involves a method for producing a nattokinase product by means of using the novel strain CGMCC No. 17895 of the present application, wherein the resulting nattokinase product can be used as a drug for dissolving thrombi. The present invention further involves the use of the nattokinase product of the present application for preparing a composition for dissolving thrombi and in a method for treating thrombi.

Abstract: Provided are a method for extracting a hirudin mutant, HV2-Lys47, from a fermentation broth of the hirudin mutant HV2-Lys47 produced by the fermentation of Escherichia coli, and purifying same, the use of the hirudin mutant HV2-Lys47 in an anticoagulated blood collection tube, and an anticoagulated blood collection tube containing the hirudin mutant HV2-Lys47. In the purification method, a membrane technology and a primary column chromatography technology are used to obtain the hirudin mutant HV2-Lys47.